Search

Your search keyword '"Backhus, Leah M."' showing total 363 results
Start Over Author "Backhus, Leah M."
363 results on '"Backhus, Leah M."'

23. KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition

Author

Binkley, Michael S, Jeon, Young-Jun, Nesselbush, Monica, Moding, Everett J, Nabet, Barzin Y, Almanza, Diego, Kunder, Christian, Stehr, Henning, Yoo, Christopher H, Rhee, Siyeon, Xiang, Michael, Chabon, Jacob J, Hamilton, Emily, Kurtz, David M, Gojenola, Linda, Owen, Susie Grant, Ko, Ryan B, Shin, June Ho, Maxim, Peter G, Lui, Natalie S, Backhus, Leah M, Berry, Mark F, Shrager, Joseph B, Ramchandran, Kavitha J, Padda, Sukhmani K, Das, Millie, Neal, Joel W, Wakelee, Heather A, Alizadeh, Ash A, Loo, Billy W, and Diehn, Maximilian

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Lung, Cancer, Clinical Research, Lung Cancer, Biomarkers, Glutaminase, Humans, Kelch-Like ECH-Associated Protein 1, Lung Neoplasms, Mutation, NF-E2-Related Factor 2, Radiation Tolerance, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

Tumor genotyping is not routinely performed in localized non-small cell lung cancer (NSCLC) due to lack of associations of mutations with outcome. Here, we analyze 232 consecutive patients with localized NSCLC and demonstrate that KEAP1 and NFE2L2 mutations are predictive of high rates of local recurrence (LR) after radiotherapy but not surgery. Half of LRs occurred in tumors with KEAP1/NFE2L2 mutations, indicating that they are major molecular drivers of clinical radioresistance. Next, we functionally evaluate KEAP1/NFE2L2 mutations in our radiotherapy cohort and demonstrate that only pathogenic mutations are associated with radioresistance. Furthermore, expression of NFE2L2 target genes does not predict LR, underscoring the utility of tumor genotyping. Finally, we show that glutaminase inhibition preferentially radiosensitizes KEAP1-mutant cells via depletion of glutathione and increased radiation-induced DNA damage. Our findings suggest that genotyping for KEAP1/NFE2L2 mutations could facilitate treatment personalization and provide a potential strategy for overcoming radioresistance conferred by these mutations. SIGNIFICANCE: This study shows that mutations in KEAP1 and NFE2L2 predict for LR after radiotherapy but not surgery in patients with NSCLC. Approximately half of all LRs are associated with these mutations and glutaminase inhibition may allow personalized radiosensitization of KEAP1/NFE2L2-mutant tumors.This article is highlighted in the In This Issue feature, p. 1775.

Published
2020

24. Pectus Excavatum: Consensus and Controversies in Clinical Practice

Author

Abramson, Horacio A., Aguiar, Wolfgang W.S., Alder, Adam C., Ambriz-González, Gabriela, Andrews, James, Backhus, Leah M., de Beer, Sjoerd A., de Campos, José Ribas M., Chu, Chih-Chun, Currie, Bruce G., Darlong, Laleng M., Dhannapuneni, Ramana, Doody, Daniel P., Elmo, Gastón, Emil, Sherif, Villacampa, Ricardo Escartín, Ferrari, Paolo A., Fortmann, Caroline, Goretsky, Michael J., Haecker, Frank-Martin, Hebra, Andre, van der Heide, Stefan M., Hendriks, Jeroen M.H., Hensens, Ab G., Heyman, Stijn R.G., van Huijstee, Pieter J., Hulsewé, Karel W.E., Infante, Maurizio V., Jansen, Yanina J.L., Jaroszewski, Dawn E., Kelly, Robert E., Jr., de Loos, Erik R., Marres, Geertruid M.H., von Meyenfeldt, Erik M., Omanik, Pavol, Oomen, Matthijs W., Peredo, Alfredo W., Perez-Alonso, David, Petersen, Claus, Pilegaard, Hans K., Prada-Arias, Marcos, Rebhandl, Winfried, Zarama, Ricardo M., Ryan, Daniel P., De Ryck, Frederic, Schewitz, Ivan, Tedde, Miguel L., Thomas, Mathew, De La Torre, Carlos A., Van Veer, Hans G.L., Vervloessem, Dirk, Vissers, Yvonne L.J., Van De Wauwer, Caroline, Wimmer, Cosmas D., Yildiran, Huseyin, Yuksel, Mustafa, Zijp, Gerda W., Janssen, Nicky, Daemen, Jean H.T., van Polen, Elise J., Coorens, Nadine A., Franssen, Aimée J.P.M., and Milanez de Campos, Jose R.

Published
2023
Full Text
View/download PDF

28. Combined Breast and Lung Cancer Screening Among Dual-Eligible Women: A Descriptive Study

Author

Yue, Tiffany, primary, Wong, Lye-Yeng, additional, Jani, Chinmay, additional, Agarwal, Lipisha, additional, Al Omari, Omar, additional, Aghagoli, Ghazal, additional, Ahmed, Alaaeldin, additional, Bhatt, Padmanabh, additional, Lee, Angela, additional, Lotz, Margaret, additional, Marmor, Hannah, additional, Paliotti, Giulia, additional, Pories, Susan, additional, Richmond, Jennifer, additional, Shula, Laura, additional, Sandler, Kim L., additional, Conley Thomson, Carey, additional, and Backhus, Leah M., additional

Published
2024
Full Text
View/download PDF

33. Greater ipsilateral rectus muscle atrophy after robotic thoracic surgery compared to open and Video-assisted thoracoscopic surgery approaches

Author

Wang, Yoyo, primary, Randle, Ryan J., additional, Bhandari, Prasha, additional, He, Hao, additional, Trope, Winston L., additional, Guenthart, Brandon A., additional, Guo, Haiwei H., additional, Liou, Douglas Z., additional, Backhus, Leah M., additional, Berry, Mark F., additional, Shrager, Joseph B., additional, and Lui, Natalie S., additional

Published
2024
Full Text
View/download PDF

40. The American Cancer Society National Lung Cancer Roundtable strategic plan: Lung cancer in women.

Author

Backhus, Leah M., Chang, Ching‐Fei, Sakoda, Lori C., Chambers, Shonta R., Henderson, Louise M., Henschke, Claudia I., Hollenbeck, Gina J., Jacobson, Francine L., Martin, Linda W., Proctor, Elridge D., Schiller, Joan H., Siegfried, Jill M., Wisnivesky, Juan P., Wolf, Andrea S., Jemal, Ahmedin, Kelly, Karen, Sandler, Kim L., Watkins, Patricia N., Smith, Robert A., and Rivera, M. Patricia

Abstract

Lung cancer in women is a modern epidemic and represents a global health crisis. Cigarette smoking remains the most important risk factor for lung cancer in all patients and, among women globally, rates of smoking continue to increase. Although some data exist supporting sex‐based differences across the continuum of lung cancer, there is currently a dearth of research exploring the differences in risk, biology, and treatment outcomes in women. Consequently, the American Cancer Society National Lung Cancer Roundtable recognizes the urgent need to promote awareness and future research that will close the knowledge gaps regarding lung cancer in women. To this end, the American Cancer Society National Lung Cancer Roundtable Task Group on Lung Cancer in Women convened a summit undertaking the following to: (1) summarize existing evidence and identify knowledge gaps surrounding the epidemiology, risk factors, biologic differences, and outcomes of lung cancer in women; (2) develop and prioritize research topics and questions that address research gaps and advance knowledge to improve quality of care of lung cancer in women; and (3) propose strategies for future research. Plain language summary: Lung cancer is the leading cause of cancer mortality in women, and, despite comparatively lower exposures to occupational and environmental carcinogens compared with men, disproportionately higher lung cancer rates in women who ever smoked and women who never smoked call for increased awareness and research that will close the knowledge gaps regarding lung cancer in women. The rising incidence and mortality of lung cancer among certain populations have resulted in a major health crisis worldwide. Despite comparatively less exposure to occupational and environmental carcinogens than their male counterparts, disproportionately high lung cancer rates in women who ever smoked and women who never smoked suggests other mechanisms influencing risk that warrant better understanding. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. Risk Model–Based Lung Cancer Screening and Racial and Ethnic Disparities in the US

Author

Choi, Eunji, primary, Ding, Victoria Y., additional, Luo, Sophia J., additional, ten Haaf, Kevin, additional, Wu, Julie T., additional, Aredo, Jacqueline V., additional, Wilkens, Lynne R., additional, Freedman, Neal D., additional, Backhus, Leah M., additional, Leung, Ann N., additional, Meza, Rafael, additional, Lui, Natalie S., additional, Haiman, Christopher A., additional, Park, Sung-Shim Lani, additional, Le Marchand, Loïc, additional, Neal, Joel W., additional, Cheng, Iona, additional, Wakelee, Heather A., additional, Tammemägi, Martin C., additional, and Han, Summer S., additional

Published
2023
Full Text
View/download PDF

44. A Report of Salaries of Academic Cardiothoracic Surgeons Based on Race and Ethnicity

Author

Pereira, Sara, Erkmen, Cherie P., Backhus, Leah M., Bostock Rosenzweig, Ian C., Bowen, Donnell, Cooke, David Tom, Erhunmwunsee, Loretta, Freeman, Kirsten A., Godoy, Luis, Kozik, Deborah, Kpodonu, Jacques, Lagisetty, Kiran H., Pelletier, Glenn J., Sihag, Smita, Wallace, Africa F., Wilder, Fatima, Wood, Douglas E., DiMaio, J. Michael, Spurlock, David J., Arora, Amit, Boffa, Daniel J., Kaiser, Larry R., Macheers, Steven K., Martin, Linda W., Misselbeck, Timothy S., Reece, T. Brett, Squiers, John J., Okusanya, Olugbenga, Mitzman, Brian A., Dexter, Elisabeth U., Fiedler, Amy, Gillaspie, Erin A., Kidane, Biniam, Kim, Min, Krueger, Anita R., Mokadam, Nahush, Nelson, David B., Pal, Jay, Rove, Jessica Y., Saddoughi, Sahar A., Serna-Gallegos, Derek R., Tong, Betty C., Vardas, Panos, Yang, Stephen C., Enofe, Nosayaba, Tompkins, Anastasiia, Cooke, David T., Freeman, Kirsten, and Merrill, Walter

Published
2024
Full Text
View/download PDF

46. Risk model‐based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model.

Author

Choi, Eunji, Luo, Sophia J., Ding, Victoria Y., Wu, Julie T., Kumar, Ashok V., Wampfler, Jason, Tammemägi, Martin C., Wilkens, Lynne R., Aredo, Jacqueline V., Backhus, Leah M., Neal, Joel W., Leung, Ann N., Freedman, Neal D., Hung, Rayjean J., Amos, Christopher I., Le Marchand, Loïc, Cheng, Iona, Wakelee, Heather A., Yang, Ping, and Han, Summer S.

Subjects
LUNG cancer, CANCER survivors, RECEIVER operating characteristic curves, PREDICTION models
Abstract

Background: Recent therapeutic advances and screening technologies have improved survival among patients with lung cancer, who are now at high risk of developing second primary lung cancer (SPLC). Recently, an SPLC risk‐prediction model (called SPLC‐RAT) was developed and validated using data from population‐based epidemiological cohorts and clinical trials, but real‐world validation has been lacking. The predictive performance of SPLC‐RAT was evaluated in a hospital‐based cohort of lung cancer survivors. Methods: The authors analyzed data from 8448 ever‐smoking patients diagnosed with initial primary lung cancer (IPLC) in 1997–2006 at Mayo Clinic, with each patient followed for SPLC through 2018. The predictive performance of SPLC‐RAT and further explored the potential of improving SPLC detection through risk model‐based surveillance using SPLC‐RAT versus existing clinical surveillance guidelines. Results: Of 8448 IPLC patients, 483 (5.7%) developed SPLC over 26,470 person‐years. The application of SPLC‐RAT showed high discrimination area under the receiver operating characteristics curve: 0.81). When the cohort was stratified by a 10‐year risk threshold of ≥5.6% (i.e., 80th percentile from the SPLC‐RAT development cohort), the observed SPLC incidence was significantly elevated in the high‐risk versus low‐risk subgroup (13.1% vs. 1.1%, p < 1 × 10–6). The risk‐based surveillance through SPLC‐RAT (≥5.6% threshold) outperformed the National Comprehensive Cancer Network guidelines with higher sensitivity (86.4% vs. 79.4%) and specificity (38.9% vs. 30.4%) and required 20% fewer computed tomography follow‐ups needed to detect one SPLC (162 vs. 202). Conclusion: In a large, hospital‐based cohort, the authors validated the predictive performance of SPLC‐RAT in identifying high‐risk survivors of SPLC and showed its potential to improve SPLC detection through risk‐based surveillance. Plain Language Summary: Lung cancer survivors have a high risk of developing second primary lung cancer (SPLC).However, no evidence‐based guidelines for SPLC surveillance are available for lung cancer survivors.Recently, an SPLC risk‐prediction model was developed and validated using data from population‐based epidemiological cohorts and clinical trials, but real‐world validation has been lacking.Using a large, real‐world cohort of lung cancer survivors, we showed the high predictive accuracy and risk‐stratification ability of the SPLC risk‐prediction model.Furthermore, we demonstrated the potential to enhance efficiency in detecting SPLC using risk model‐based surveillance strategies compared to the existing consensus‐based clinical guidelines, including the National Comprehensive Cancer Network. Given the rapidly growing number of lung cancer survivors who are now at high risk of developing second primary lung cancer (SPLC), previous studies have identified SPLC risk factors and developed SPLC risk‐prediction models, but they lack insight into real‐world validation to help improve clinical decision‐making in SPLC surveillance for lung cancer survivors. Using a large, hospital‐based real‐world cohort of lung cancer survivors, the authors validated the predictive accuracy of an SPLC risk‐prediction model (area under the curve of 0.81), that can identify high‐risk lung cancer survivors for SPLC and can be incorporated into clinical decision‐making for SPLC surveillance to improve the systematic management of lung cancer survivors. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. Second Primary Lung Cancer Among Lung Cancer Survivors Who Never Smoked

Author

Choi, Eunji, primary, Su, Chloe C., additional, Wu, Julie T., additional, Aredo, Jacqueline V., additional, Neal, Joel W., additional, Leung, Ann N., additional, Backhus, Leah M., additional, Lui, Natalie S., additional, Le Marchand, Loïc, additional, Stram, Daniel O., additional, Liang, Su-Ying, additional, Cheng, Iona, additional, Wakelee, Heather A., additional, and Han, Summer S., additional

Published
2023
Full Text
View/download PDF

49. Risk model‐based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model

Author

Choi, Eunji, primary, Luo, Sophia J., additional, Ding, Victoria Y., additional, Wu, Julie T., additional, Kumar, Ashok V., additional, Wampfler, Jason, additional, Tammemägi, Martin C., additional, Wilkens, Lynne R., additional, Aredo, Jacqueline V., additional, Backhus, Leah M., additional, Neal, Joel W., additional, Leung, Ann N., additional, Freedman, Neal D., additional, Hung, Rayjean J., additional, Amos, Christopher I., additional, Le Marchand, Loïc, additional, Cheng, Iona, additional, Wakelee, Heather A., additional, Yang, Ping, additional, and Han, Summer S., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results